Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
Infective endocarditis (IE) caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SARV) has been reported worldwide. We report the successful treatment of a pediatric patient with SARV IE and characterization of the infecting strain. The MIC of vancomycin rose from 1.5 to 2 microg/ml, and the SARV was confirmed by population analysis.
Chi
Chia-Yu
CY
Division of Clinical Research, National Health Research Institutes, Tainan, Taiwan.
Lauderdale
Tsai-Ling
TL
Wang
Shih-Min
SM
Wu
Jing-Ming
JM
Yang
Yu-Jen
YJ
Liu
Ching-Chuan
CC
D000081:Acetamides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002675:Child, Preschool; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology*; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D005672:Fusidic Acid / Q000627:therapeutic use; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D020713:Vancomycin Resistance
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D005672:Fusidic Acid; D000069349:Linezolid